OrbiMed closes sixth flagship fund on $950m

OrbiMed’s most recent investment was earlier this month when it participated in a $53 million Series B financing for ORIC Pharmaceuticals.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this